



Treatment of Mastitis in Dairy Cattle

Guest Editor:

Prof. Dr. Volker Krömker

Section for Production, Nutrition
and Health, University of
Copenhagen, Copenhagen,
Denmark

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editor

Dear Colleagues,

Bovine mastitis is one of the most costly diseases affecting the dairy industry and is the most common condition affecting dairy cows where antibiotics are used. Also, it is a painful disease that affects animal welfare. Over recent decades, the aims of mastitis treatment have been focused on maximizing cure rates, which has led to relatively simple treatment criteria resulting in predominantly blanket antimicrobial treatment. Not only uncritical substances are used. Only through careful and systematic scientific work can the therapy of mastitis be more targeted, so that comparable or even better cure rates can be achieved with fewer antibiotic doses. This issue seeks manuscripts that will help in the development of an evidence-based targeted antibiotic therapy for mastitis in cattle. This includes not only manuscripts on clinical and pharmacological issues, but also those on decision-making tools, antimicrobial resistance, knowledge transfer in practice, economics of evidence-based therapies and animal welfare aspects.

Keywords: mastitis therapy, antimicrobial resistance, evidence based antibiotic treatment, bacteriological cure, animal welfare





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi